The split nature of tumor-infiltrating leukocytes
Implications for cancer surveillance and immunotherapy

Telma Lança and Bruno Silva-Santos

Keywords: tumor-infiltrating lymphocyte, cytotoxicity, T helper cells, interferon γ, angiogenesis, prognostic marker

Abbreviations: TIL, tumor-infiltrating lymphocyte; Th, helper T cell; Treg, regulatory T cell; NK, natural killer cell; MDSC, myeloid-derived suppressor cell; IFN, interferon; IL, interleukin; VEGF, vascular endothelial growth factor; ACT, adoptive cell therapy

An important development in tumor immunology was the identification of highly diverse tumor-infiltrating leukocyte subsets that can play strikingly antagonistic functions. Namely, “anti-tumor” vs. “pro-tumor” roles have been suggested for Th1 and Th17 subsets of CD4+ T cells, Type I or Type II NKT cells, M1 and M2 macrophages, or N1 and N2 neutrophils, respectively. While these findings are being validated in cancer patients, it is also clear that the balance between infiltrating CD8+ cytotoxic and Foxp3+ regulatory T cells has prognostic value. Here we review the pre-clinical and clinical data that have shaped our current understanding of tumor-infiltrating leukocytes.

Introduction

A fundamental principle of cancer immune surveillance is that tumors are infiltrated by leukocytes, particularly lymphocytes, capable of recognizing and targeting transformed cells, thus leading to their elimination before the tumor becomes clinically apparent. Moreover, the efficacy of immunotherapy against established tumors presumably depends on lymphocyte recruitment and effector function within the tumor bed. However, a major obstacle to anti-cancer therapy is the local immune suppression commonly found within the tumor microenvironment. While earlier work had focused on tumor cell-derived factors that inhibit the local immune response, the past few years have demonstrated a dramatic contribution of leukocytes themselves to this “pro-tumor” environment. Recent reports have further clarified this paradoxical leukocyte behavior by identifying a very heterogeneous set of subpopulations, both of lymphoid and myeloid origin, that can play strikingly antagonistic roles within the tumors they co-infiltrate.

The prototypic anti-tumor function, displayed by various lymphocyte subsets (Fig. 1), is cytotoxicity via the perforin/ granosome system or, alternatively, by engaging death receptors (such as Fas). These properties are further promoted by interferon γ (IFNγ), the signature Th1 cytokine that is, in fact, secreted by multiple cell types (see below), often together with tumor necrosis factor (TNF). By contrast, cytokines such as TGFβ or IL-10 are highly immunosuppressive, and other secreted factors, like VEGF, directly promote angiogenesis and thus tumor growth (Fig. 2).

The detailed characterization of gene expression and cytokine profiles in leukocyte populations isolated from tumor biopsies (or draining lymph nodes) has been instrumental in revealing the heterogeneity of tumor-infiltrating leukocytes, both of lymphoid and myeloid nature, which we will discuss in this review.

Many of the key studies on tumor-infiltrating leukocytes have been performed in mouse tumor models. Although they present several important limitations, including the artificial homogeneity and laboratory selection of tumor cell lines used in transplantable models, the lack of relevant physiology (including interactions between autologous tumors and immune cells) in xenograft models, and the commonly short span (2–4 weeks) of all these tumor development experiments, animal models provide a unique opportunity to directly promote angiogenesis and thus tumor growth (Fig. 4).

The detailed characterization of gene expression and cytokine profiles in leukocyte populations isolated from tumor biopsies has been instrumental in revealing the heterogeneity of tumor-infiltrating leukocytes, both of lymphoid and myeloid nature, which we will discuss in this review.

The Traditional Players: NK, CD8+ T and Th1 Cells

It has been known for three decades that NK cells and CD8+ T lymphocytes, including those extracted from tumor biopsies, can efficiently kill transformed cells. Collectively, these killer lymphocytes recognize two important types of tumor antigens (among others): processed peptides presented by MHC Class Ia proteins via TCR and, and non-classical (Class Ib) MHC proteins via NKG2D. The latter, which is expressed on NK, CD8+ and also γδ T cells, has been recently shown to be a key genetic determinant of cancer immune surveillance.
NK and CD8<sup>+</sup> cells provide highly complementary anti-tumor strategies. Indeed, as demonstrated by the seminal work of Kärre and Kiesling, the downregulation of MHC class Ia, which is a common mechanism of evasion against CD8<sup>+</sup> cells, renders tumors more susceptible to NK cell-mediated lysis. This "missing self" recognition by NK cells is based on a set of MHC class Ia-specific inhibitory receptors that include killer cell immunoglobulin-like receptors (KIRs) in humans, lectin-like Ly49 molecules in mice, and CD94/NKG2A heterodimers in both species; in fact, NK cells express a complex repertoire of inhibitory and activating receptors that calibrate this anti-tumor function, while ensuring self-tolerance. In result, NK cells eliminate tumors that lack MHC class Ia expression; or that overexpress ligands for activating NK receptors like NKG2D or the natural cytotoxicity receptors NKp30, NKp44 and NKp46. Furthermore, NK cells express high levels of low-affinity Fc receptor for IgG (CD16), which allows them to mediate antibody-dependent cell-mediated cytotoxicity (ADCC).

Figure 1. Anti-tumor infiltrating leukocytes and molecular mechanisms of action. Representation of the main anti-tumor lymphoid and myeloid cells. N1 and M1 refer to neutrophil and macrophage subsets, respectively; γδ T and Th1 refer to IFNγ-producing γδ and CD4<sup>+</sup> T cells, respectively. Depicted are also molecules produced by these leukocytes, including cytokines that impact on cell differentiation and expansion, and chemokines that control their recruitment/infiltration into tumors.

NK cells have been described to infiltrate various types of tumors in the skin, lung, gut and kidney. Recent data on human NK cells infiltrating highly aggressive non-small cell lung cancers (NSCLC) showed a profound alteration of their phenotype, with decreased ability to degranulate and to produce IFNγ, when compared with NK cells from distal lung tissues or blood from the same patients or from healthy donors. This functional impairment of NK-TILs correlated with decreased expression of NKp30, NKp80, DNAM-1, CD16 and ILT2 receptors. Interestingly, among these, NKp30 has been shown to affect the prognosis of gastrointestinal stromal tumors through a specific pattern of alternative splicing. Various immunotherapeutic strategies have been proposed to tackle the common defects of NK cell activity in cancer patients: activation of endogenous NK cells (with cytokines like IL-2, IL-15 and IL-18), NK-cell adoptive immunotherapy, NK-cell-based donor lymphocyte infusions and allogenic stem cell transplantation (SCT). Although globally the objective responses...
have been disappointing, some data from allogenic and, more recently, haploidentical hematopoietic SCT have shown clinical (in the absence of adverse) effects mediated by NK cells. This inspires further translational studies aimed at enhancing NK cell recruitment to tumors and their functional activity in situ.

With regard to CD8+ T cell-based immunotherapy, many recent efforts have focused in activating and expanding CD8+ tumor-infiltrating lymphocytes (TILs) ex vivo and then re-infusing them into the cancer patient—adoptive cell therapy (ACT). ACT of CD8+ TILs into lymphodepleted metastatic melanoma patients has shown very high objective response rates, ranging from 50% up to 81%. In fact, TIL-ACT (combined with high doses of IL-2) has mediated cancer regression in 49–72% of melanoma patients, and durable complete responses, beyond 3–7 y, are currently ongoing in 40% of the patients.

In pre-clinical models, adoptively transferred naïve CD8+ cells were shown to infiltrate melanoma lesions, be activated in situ and differentiate into functional cytotoxic T lymphocytes (CTLs). The naïve status of the infused population appeared to be an important parameter, as the differentiation stage of CTLs inversely correlated with their anti-tumor efficacy in vivo. The enhanced anti-tumor function of naïve T cells was related to sustained effector cell development, prolonged cytokine production, and increased expansion in vivo.

Transduction of tumor antigen-specific TCRs or chimeric antigen receptors (CARs) represent exciting prospects to increase the efficacy of cytotoxic ACT. These strategies have thus far enabled cancer regression in patients with metastatic melanoma, synovial sarcoma, neuroblastoma and refractory lymphoma or leukemia.

In addition to cytotoxicity, IFNγ secretion is a key anti-tumor function of CD8+ and NK cells, who share this property with various other lymphocyte populations, most notably "helper type 1" (Th1) CD4+ cells. These were first described 25 y ago in the context of the "Th1/Th2" paradigm of immunity to infection, and since then clearly implicated in promoting anti-tumor responses: Th1 cells enhance the cytotoxic functions of NK and CD8+ cells, upregulate MHC Class I expression in tumor cells (a direct effect of IFNγ), and support CD8+ cell proliferation through the secretion of IL-2. Moreover, Th1 cells condition

| Tumor cell proliferation | Angiogenesis | Invasion |
|--------------------------|-------------|---------|
| Proteinases              |             |         |
| Th17 CD4+                |             |         |
| N2                       |             |         |
| M2                       |             |         |
| IL-17                    |             |         |
| IL-18                    |             |         |
| IL-6                     |             |         |
| CCL17                    |             |         |
| CCL22                    |             |         |
| CCL24                    |             |         |
| Treg CD4+                |             |         |
| MDSC                     |             |         |
| Anti-tumor lymphocytes   |             |         |

Figure 2. Pro-tumor infiltrating leukocytes and molecular mechanisms of action. Representation of the main pro-tumor lymphoid and myeloid cells. N2 and M2 refer to neutrophil and macrophage subsets, respectively. Th17 and Th1 refer to IL-17-producing γδ and CD4+ T cells, respectively. Depicted are also molecules produced by these leukocytes, including cytokines that impact on cell differentiation and expansion, and chemokines that control their recruitment/infiltration into tumors.
the antigen-presenting capacity of DCs and macrophages, thus shaping the CTL response. In fact, the combination of Th1 cell therapy with local radiation therapy augmented the generation of tumor-specific CTL at the tumor site and induced a complete regression of subcutaneous tumors.17

“New” Effector TILs: γδ T, NKT and Th17 Cells

The “Th1/Th2” paradigm for CD4+ T cell differentiation has been recently revised with the addition of Th17 cells, characterized by the production of interleukin-17 (IL-17). IL-17-deficient mice were shown to be more susceptible (than wild type animals) to tumor growth and lung metastasis.18,19 Adoptive transfer studies from the Restifo lab showed that in vitro generated Th17 cells were more efficient at eradicating tumors than Th1 cells,20 and this was recently associated with stem cell-like properties of Th17 cells.21 Importantly, adoptively transferred Th17 cells gave rise in vivo to Th1-like effector cell progeny,22 and IFNγ was actually necessary for the protective effects of adoptively transferred Th17 cells.23 These data suggest that acquisition of Th1-like properties are required for an anti-tumor function by Th17 cells.

In stark contrast to the previous studies, IL-17-deficient mice presented reduced tumor growth in other models such as B16 melanoma and MB49 bladder carcinoma,23 DMBA/TPA-induced skin carcinoma,24 or in a spontaneous intestinal tumor model (driven by a mutation in the tumor suppressor gene APC).24

The pro-tumor functions of IL-17 have been rightly linked to angiogenesis: IL-17 has been shown to act on endothelial, stromal and tumor cells to induce the expression of pro-angiogenic factors like VEGF, Angiogenins, PGE2 and IL-8, and thus promote tumor vascularization.25 The precise conditions that determine pro- vs. anti-tumor functions of Th17 TILs remain unclear and require further investigation.

Although Th17 cells are important providers of IL-17, this cytokine can be abundantly produced by other tumor-infiltrating leukocyte populations. Namely, murine γδ T cells can be the major source of IL-17, not only in homeostatic conditions,26 but also upon infection or tumor challenge.27,28 Like for Th17 cells, the role of IL-17 produced by γδ cells within the tumor microenvironment is controversial: it has been associated both with angiogenesis and promotion of tumor growth,29,30 and with CD8+ T cell recruitment and the therapeutic effects of chemotherapy against several subcutaneous tumor lines.28,29

While the recently discovered ability of γδ T cells to make IL-17 has attracted much attention, these lymphocytes were previously characterized as strong cytotoxic and IFNγ-producing cells, and thus prototypic anti-tumor mediators. Consistent with this, seminal work by Girardi and Hayday showed a decade ago that mice lacking γδ T cells were significantly more susceptible to chemically induced tumors.31 This phenotype was subsequently extended to transplantable,32 spontaneous33 and transgenic34 tumors.

In the murine B16 melanoma model, γδ T cells were shown to infiltrate tumor lesions already at day 3 post-transplantation and to provide a critically early source of IFNγ.35 With the above-mentioned findings on IL-17γδ-TILs,36,37 a more detailed characterization of γδ-TILs is therefore required in a wider set of pre-clinical tumor models. This should take into account the two functional γδ T cell subsets recently identified on the basis of CD327 (and CCR6) expression: CD27γδ T cells make IFNγ but not IL-17, whereas IL-17 production is restricted to CD27γδ T cells.38

γδ T cell-based clinical trials have thus far concentrated on the highly IFNγ-polarized (and cytotoxic) Vγ9Vδ2 subset that constitutes more of γδ cells circulating in the human peripheral blood. As these cells are specifically reactive to non-peptidic phosphoantigens, they can be selectively activated and expanded both in vitro (for ACT) and in vivo. In cancer patients, γδ T cell-based immunotherapy has thus far produced objective responses in the range of 10 to 33%.39 Future research should also take into account the important roles played by NK receptors, including NKp3039 and NKp46,40 in tumor cell recognition by Vγ9Vδ2 cells and by V81 cells (which predominate in tissues).

NKT cells also employ NK receptors, as well as CD1d-restricted TCRs to recognize tumor targets. The vast majority of these T cells are canonical or invariant NKT (type I NKT) cells that possess a specific TCR rearrangement (Vα14Jα18 in mice; Vα24Jα18 in humans), associated with VJ chains of limited diversity. All the other NKT cells that are CD1d-restricted and do not express this invariant TCR are called Type II NKT cells.39,41

While the recently discovered ability of γδ T cells to make IL-17 has attracted much attention, these lymphocytes were previously characterized as strong cytotoxic and IFNγ-producing cells, and thus prototypic anti-tumor mediators. Consistent with this, seminal work by Girardi and Hayday showed a decade ago that mice lacking γδ T cells were significantly more susceptible to chemically induced tumors.31 This phenotype was subsequently extended to transplantable,32 spontaneous33 and transgenic34 tumors.

The Inflammatory Phagocytes: TAMs and TANs

Macrophages and neutrophils are important myeloid cells of the innate immune system and major drivers of inflammatory responses. Given the long-established association between cancer and inflammation, it is not surprising that tumor-associated macrophages (TAMs) and neutrophils (TANs) can have a great impact on the course of tumor progression. While most studies have associated TAM and TAN infiltration with promotion of tumor cell growth, some other reports have proposed some
anti-tumor roles. Once again, these opposing behaviors may be explained by heterogeneous TAM and TAN phenotypes, with distinct intra-tumor dynamics in various models.

Mirroring Th1/Th2 polarization of CD4+ T cells, two distinct subsets of macrophages have been recognized: the "classical" activated (M1) macrophage phenotype and the "alternatively" activated (M2) macrophage phenotype. IFN-γ drives the polarization toward M1 macrophages, which are characterized by abundant production of TNF, IL-12 and IL-23, CXCL9 and CXCL10 (cytokines and oxygen species) and high expression of MHC class II and costimulatory molecules (making them efficient antigen-presenting cells). Conversely, IL-4 polarizes macrophages toward the M2 phenotype, which is associated with low levels of IL-12 but high levels of IL-10, IL-RA and IL-1 decoy receptor. M2 cells also produce CCL17, CCL22 and CCL24, which results in the recruitment of Tregs and TH2 cells, eosinophils and basophils. The balance between M1 and M2 phenotypes seems to be controlled by NKfB signaling. Thus, NKfB targeting switched macrophages from an M2 to an M1 phenotype and led to ovarian tumor regression in vivo. Nonetheless, the most frequent TAM phenotype seems to be M2. Consistent with this, TAM depletion was associated with improved anti-tumor immunity in models of metastatic breast, colon and non-small lung cancers.

The pro-tumor roles of M2 macrophages derive from various molecular mechanisms, including the production of the pro-angiogenic mediator semaphoring 4D and the invasive proteases cathepsin B and S. In the case of neutrophils, besides secreting cytokines and chemokines (such as IL-1β, IL-8, and IL-12), they produce large amounts of proteases that remodel the extracellular matrix and promote the release of pro-angiogenic VEGF, thus supporting tumor cell growth and invasiveness. Particularly important neutrophil proteases are elastase and matrix metalloproteinases MMP-8 and MMP-9.

Despite being widely accepted as pro-tumor mediators based on multiple pre-clinical and clinical studies, a dual nature of tumor-infiltrating neutrophils has also been suggested recently. Thus, anti-tumor N1 and pro-tumor N2 subsets were described and modulated within tumors by TGF-β or IFN-γ. Consistent with such a complex neutrophil activity within the tumor microenvironment, the concentration of reactive oxygen species also seems to determine either pro-tumor (genotoxicity at modest concentrations) or anti-tumor (cytotoxicity at high concentrations) effects. Consequently, the depletion of total neutrophils can lead to either reduced or increased tumor burden, further illustrating the globally paradoxical roles of tumor-infiltrating leukocytes.

Immunosuppressive Leukocytes: Treg and MDSCs

Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid progenitors and precursors of macrophages, granulocytes and dendritic cells, which are better characterized by their strong capacity to inhibit both innate and acquired immunity, particularly T-cell responses. Murine MDSCs can be identified by the expression of Gr1 (includes Ly6C and Ly6G), macrophage and neutrophil markers, respectively, and CD11b (characteristic of macrophages). In humans, MDSCs are characterized by a CD11b+ CD33+ CD14+ HLA-DR phenotype. Tumors produce various factors that promote MDSC expansion, such as IL-6, VEGF or GM-CSF, whereas they get further activated by local IFN-γ, IL-1β or Toll-like receptor (TLR) signals.

MDSCs use a diversity of mechanisms to suppress T-cell function, including the uptake of arginine and cysteine (essential amino acid for T cell activation) and the nitration of the TCR. In addition, MDSCs have been recently shown to directly support tumor growth by promoting the epithelial-to-mesenchymal transition in melanocytes.

The possibility of improving anti-tumor immune responses by targeting MDSCs has been explored in pre-clinical models. One of the chemical drugs that seem to be more effective for MDSC depletion was 5-fluorouracil (5-FU). In a model of thymoma EL4 cells transplanted subcutaneously, tumor-bearing mice treated with 5-FU showed reduced number of MDSC in tumor lesions. This associated with prolonged mouse survival and enhanced intratumoral CD8+ T cell antigen-specific capacity to produce IFN-γ. Interestingly, combination therapy with an agent (cylophosphamide, CTX) that reduces Tregs led to a synergistic protective effect. Consistent with this, another study showed that inhibition of MDSC and Treg function within B16 melanomas using blocking antibodies to CTLA-4 (already in clinical use—ipilimumab—in late-stage melanoma) and to PD-1 reduced tumor development and increased mouse survival.

Foxp3+ Tregs are well known to suppress the activation, proliferation and effector functions (such as cytokine production) of a wide range of immune cells, including CD8+ and CD4+ T cells, NK and NKT cells, B cells, macrophages and DCs. Suppressive functions displayed by Tregs include contact-dependent mechanisms, such as those that involve CTLA-4, PD-1 and GITR, and cytokine-mediated mechanisms such as TGF-β, IL-10 and IL-35. TGF-β is particularly critical since, besides being strongly immunosuppressive, creates a potent positive feedback mechanism by instructing the differentiation of "inducible" Tregs.

Experimental Treg depletion has been usually accomplished using anti-CD25 monoclonal antibodies, since there is a good correlation between CD25 and Foxp3 expression within CD4+ T cells (although activated effector cells also upregulate CD25).

Prophylactic Treg depletion in renal cell carcinoma and MCA carcinoma was shown to reduce tumor growth, with protection being dependent on CD8+ and NK cells.

While most studies have concentrated on the immunosuppressive function of Tregs, two recent reports have shown that they can also act by directly promoting tumor growth and discrimination. Thus, Treg TILs in ovarian cancer they secrete VEGF that promotes endothelial cell proliferation, and in breast cancer they produce RANKL, which associates with lung metastasis.

Importantly, the latter study is one of many that demonstrates that Treg accumulation within tumors is a marker for poor clinical outcome.
The Prognostic Value of Tumor-Infiltrating Leukocytes in the Clinic

Although a favorable association of high numbers of TILs in the primary tumors had been generally reported for decades in many human cancers, TILs had never reached the level of recognized prognostic marker (or proof for cancer immunosurveillance) probably due to their phenotypic and functional heterogeneity.67 The recent observations that specific immune parameters have better specificity and predictive value than standard staging systems, highlights the importance of the endogenous immune response in determining the clinical outcome. This may help to modify current classifications, and—most importantly—to identify the patients who would benefit the most from adjuvant immunotherapy.

Considering the data reviewed above, it is tempting to assume that good prognostic associates (for example) with CD8+ and NK cells, whereas bad prognosis is linked to the accumulation of Tregs and MDSCs. Moreover, given the functional heterogeneity within many leukocyte populations, clearly distinct outcomes could be expected from Th1 vs. Th2 or Th17 CD4+ subsets, M1 vs. M2 macrophages, N1 vs. N2 neutrophils. This level of refinement is obviously incompatible with traditional immunohistochemistry of cancer patient samples, thus requiring additional techniques like flow cytometry and molecular biology to provide an adequate characterization of tumor-infiltrating leukocytes. Furthermore, detailed imaging may also be important as to define the localization of TILs within the tumor mass. For example, in a pre-clinical model, CD8+ T cells were recently shown to be trapped in the stroma and thus excluded from the core of tumor due to post-translational modifications (nitrilation) of the chemokine CCL2.68 Of note, novel drugs that inhibited CCL2 nitrilation facilitated CD8+ T cell infiltration and tumor regression.

The most comprehensive clinical studies correlating tumor-infiltrating leukocytes with disease outcome have been performed in colorectal cancer, where the general conclusion has been that disease free overall survival is positively associated with a coordinated Th1/CD8+ T cell infiltration67 (Table 1). A similar result was reached for breast cancer67,69 and for hepatocellular carcinoma, where NK markers and the chemokines CCL2, CCL5 and CXCL10 were additional immune signatures predictive of patient survival (at early stages of the disease).70

By contrast, Treg infiltration has been generally associated with poor prognosis (Table 2). In ovarian carcinoma, melanoma, breast cancer, Hodgkin lymphoma and glioblastoma, the presence and frequency of Tregs correlated with tumor grade and with reduced patient survival.71 These studies also highlighted the potential role for CCL17 and CCL22 (ligands for the chemokine receptor CCR4) in recruiting Tregs into tumors. The combined value of quantifying both CD8+ and Treg TIL (antagonistic) subsets as prognostic of disease-free survival was demonstrated in hepatocellular carcinoma72 and colorectal cancer.73 However, in some cancer types, such as colorectal73 and head and neck carcinomas,74 Treg accumulation within tumors has been associated with favorable prognosis. This was suggested to be due to a dominant effect in suppressing infection-associated inflammation at mucosal interfaces.75 Nonetheless, positive associations between survival and Treg numbers were also observed upon immunohistochemical analysis of biopsies from four types of lymphoma patients.76,77

Whereas Th2 infiltration has been associated with poor prognosis in pancreatic cancer,85 the role of Th17 TILs in human cancer is much more controversial. On one hand, Th17 cell infiltration has been correlated with poor prognosis in prostate cancer79 and in hepatocellular carcinoma80 on the other, it has been associated with better overall survival in ovarian cancer80 and in esophageal squamous cell carcinoma.81 While the reasons for these discrepancies are unclear, it may be interesting to assess the co-production of IL-17 and IFNγ by Th17 cells, as well as their association with CD8+ T cell recruitment.

Finally, a recent study attempted to integrate the prognostic values of Th1, Th2 and Th17 TILs by hierarchical clustering of signature gene transcripts in colorectal tumor specimens. The results showed that: the Th2 cluster did not correlate with prognosis; patients with high expression of the Th1 cluster had prolonged disease-free survival; and patients with high expression of Th17 cluster had poor prognosis.82 In the future, we believe

Table 1. Tumor-infiltrating leukocytes associated with good prognosis for cancer patients

| TIL | Cancer Type | References |
|-----|-------------|------------|
| CD8+ | colorectal cancer | 74, 86, 87 |
| | hepatocellular carcinoma | 71, 72, 73 |
| | esophageal carcinoma | 84, 88, 89 |
| Tregs (CD4+ | colorectal cancer | 75 |
| | esophageal carcinoma | 84 |
| | head and neck carcinoma lymphoma | 78, 79 |
| γδ T cells | ovarian carcinoma | 90 |
| B cells | breast cancer | 69 |
| NK cells | esophageal carcinoma | 84 |
| | hepatocellular carcinoma | 71 |

Table 2. Tumor-infiltrating leukocytes associated with poor prognosis for cancer patients

| TIL | Cancer Type | References |
|-----|-------------|------------|
| Th17 (CD4+) | colorectal cancer | 85 |
| | hepatocellular carcinoma | 82 |
| | prostate cancer | 81 |
| Th2 (CD4+) | pancreatic cancer | 80 |
| Tregs (CD4+) | colorectal cancer | 74 |
| | hepatocellular carcinoma | 72 |
| | breast cancer | 91 |
| MDSCs | esophageal, pancreatic and gastric | 93 |
| Macrophages | breast cancer | 94 |
| Neutrophils | renal cell carcinoma | 95 |
that will be highly informative and important to collect similar data in many other cancer types.

Conclusions

The identification of highly diverse tumor-infiltrating leukocyte subsets and their distinct, sometimes antagonistic, functions in the tumor niche has been an important development in Oncoimmunology. This has allowed a better dissection and understanding of the interactions between immune components and tumor cells, not only in animal models but also in patients. We are now approaching an era where immune parameters will likely constitute some of the best prognostic markers for cancer progression/ regression. This will also allow a more insightful selection of patients to undergo immunotherapy as adjuvant treatment. Notwithstanding, many basic aspects of TIL biology still need to be clarified as to resolve key controversies in the field, such as the paradoxical behaviors of Th17 and γδ T cells (among others) in distinct cancer models/ types. Clinical studies must now routinely include in-depth population phenotyping and gene expression analysis in order to address the striking heterogeneity of the immune infiltrate. These factors will be crucial to clinically promote an anti-tumor microenvironment and thus increase the success of cancer immunotherapy.

Acknowledgments

We thank Dan Pennington and Margarida Rea for inspiring discussions on this topic. Our research is supported by the European Research Council and the European Molecular Biology Organization (Young Investigator Programme), T.L. is also supported by a PhD fellowship from Fundaçao para a Ciência e Tecnologia (Portugal).
43. Mantovani A, Germano G, Marchesi F, Locatelli M, Birona P. Cancer promoting tumor-necrotic macrophages: new view and open questions. Eur J Immunol 2011; 41:3495-503; PMID:22086534; http://dx.doi.org/10.1002/eji.201043894

44. Bower SK, Maniatis T. Macrophage plasticity and association with lymphoid organs: cancer as a paradigm. Nat Immunol 2011; 11:89-90; PMID:21269828; http://dx.doi.org/10.1038/ni.1937

45. Hagemann T, Lenormand T, McNichol I, Charles KA, Ruthe H, Thompson RG, et al. ‘Reprogramming’ tumor-associated macrophages by targeting NK-Tpked. J Exp Med 2008; 205:1253-64; doi.org/10.1084/jem.20081018

46. Leichsenring A, Lang SM, Wohlfart SL, Gerhard W, Muller M, Voss G, et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Oncol 2006; 24:1626-34; PMID:16622233; http://dx.doi.org/10.1200/JCO.2006.03.1471

47. Soria JB, Gress J, Cranin G, Copinschi G, Cangro C, Ansel K, et al. Tumor angiogenesis and progression are enhanced by Sirtuin1 produced by tumor-associated macrophages. J Exp Med 2008; 205:1673-85; PMID:18495045; http://dx.doi.org/10.1084/jem.20070762

48. Geocha Y, Wang H, Gadsb J, Show T, Hunter KE, Gaffney AL, et al. αT-β(+) induces carpomatopoietin pre-1 expression in tumour-associated macrophages to promote cancer growth and invasion. Gene Dev 2010; 24:241-55; PMID:20806976; http://dx.doi.org/10.1101/gad.184710

49. Houghton AM. The paradox of tumor-associated neutrophil-mediated tumor growth with cytokine-based therapy: novel mechanistic insight to clinical application. Cancer Res 2011; 71:6116-26; http://dx.doi.org/10.1158/0008-5472.CAN-10-3262

50. Leach M, Gatto M. The CAR1 on breast USLR is a nondruggable determinant of breast/lymphoid leukemia susceptibility to ganciclovir T cell cytolyis. Blood 2010; 115:2525-31; PMID:20162620; http://dx.doi.org/10.1182/blood-2009-06-212372

51. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Trends Immunol 2011; 32:19-25; PMID:21159627; http://dx.doi.org/10.1016/j.it.2010.03.015

52. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Swann JB, et al. Targeting tumor-associated macrophages by targeting CD27 is a thymic determinant of the γδ T-cell phenotype by TGF-beta: mechanistic insight to clinical application. Cancer Res 2011; 71:1673-85; PMID:21326202; http://dx.doi.org/10.1158/0008-5472.CAN-10-1372

53. Augenlicht LH, et al. Gamma delta T cells provide an innate immuno-surveillance mechanism against mouse tumor model. J Immunol 2008; 180:6044-53; PMID:18424725

54. Jablonska J, Leschner S, Westphal K, Lienenklaus S, Lotz M, Wieland T, et al. Neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle 2010; 9:1732-7; PMID:20856220; http://dx.doi.org/10.1042/2011-02-339135

55. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Gocheva V, et al. Human solid tumors contain a class of tumor-infiltrating antigen-specific T cells and gammadelta T cells. J Exp Med 2004; 199:1267-85; PMID:15319012; http://dx.doi.org/10.1084/jem.20031981

56. Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, et al. Tumor necrosis factor-alpha (TNF-α) expression of neutrophil elastase in a mouse model of prostate cancer. J Immunol 2008; 180:3529-40; PMID:18495045; http://dx.doi.org/10.1084/jem.20070762

57. Hafler DA. Protective immunosurveillance and therapeutic antigen recognition by T cells demonstrated in a mouse model of pancreatic cancer. J Immunol 2006; 181:6444-53; PMID:16384275

58. Ribor JC, Andrews P, Pang DI, Neves JF, Peperzak V, Augenlicht LH, et al. Human solid tumors contain a class of tumor-infiltrating antigen-specific γδ T cells and gammadelta T cells. J Exp Med 2004; 199:1267-85; PMID:15319012; http://dx.doi.org/10.1084/jem.20031981

59. cosplay J, Gress J, Cranin G, Copinschi G, Cangro C, Ansel K, et al. Tumor angiogenesis and progression are enhanced by Sirtuin1 produced by tumor-associated macrophages. J Exp Med 2008; 205:1673-85; PMID:18495045; http://dx.doi.org/10.1084/jem.20070762

60. Exley MA, Nakayama T. NKT-cell-based immuno-therapies: new vistas and open questions. Eur J Immunol 2011; 41:6495-503; PMID:21980263; http://dx.doi.org/10.1002/eji.201043894

61. Lança T, Correia DV, Moita CF, Raquel H, Neves JF, Peperzak V, et al. Regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011; 32:19-25; PMID:21159627; http://dx.doi.org/10.1016/j.it.2010.03.015

62. Teng MW, Swann JB, von Scheidt B, Sharkey J, Zelnik M, MacLachlan N, et al. Multiple antigen mechanisms dominate of prophylactic epidemiology T cell deletion. Clin Immunol 2010; 138:265-74; PMID:20332266; http://dx.doi.org/10.1016/j.coi.2010.12.011

63. Faccenda A, Pong H, Hagensen IS, Baki K, Barchetti A, Wang LP, et al. Tumor hypoxia promotes tolerance and antigen Escape from T cells and γδ T cells. Nature 2011; 475:273-80; PMID:21275950; http://dx.doi.org/10.1038/nature10797

64. Facciabene A, Peng X, Hagensen IS, Baki K, Barchetti A, Wang LP, et al. Tumor hypoxia promotes tolerance and antigen escape from T cells and γδ T cells. Nature 2011; 475:273-80; PMID:21275950; http://dx.doi.org/10.1038/nature10797

65. Tan W, Zheng W, Stummer A, Groenendijk S, Cheng DJ, Hoffman HM, et al. Targeting-stimulating regulatory T cell in melanoma. The first hurdle towards effective immunotherapy! Lancet Oncol 2012; 13:43-52; PMID:22227723; http://dx.doi.org/10.1016/j.cell.2010.03.015

66. Houghton AM. Matrix metalloproteinases: regulators of the tumor microenvironment. Trends Immunol 2011; 32:19-25; PMID:21159627; http://dx.doi.org/10.1016/j.it.2010.03.015

67. Augenlicht LH, et al. Human solid tumors contain a class of tumor-infiltrating antigen-specific T cells and gammadelta T cells. J Exp Med 2004; 199:1267-85; PMID:15319012; http://dx.doi.org/10.1084/jem.20031981

68. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Gocheva V, et al. Human solid tumors contain a class of tumor-infiltrating antigen-specific T cells and gammadelta T cells. J Exp Med 2004; 199:1267-85; PMID:15319012; http://dx.doi.org/10.1084/jem.20031981

69. Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard C, Robert S, et al. Human solid tumors contain a class of tumor-infiltrating antigen-specific T cells and gammadelta T cells. J Exp Med 2004; 199:1267-85; PMID:15319012; http://dx.doi.org/10.1084/jem.20031981

70. Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, et al. Tumor necrosis factor-alpha (TNF-α) expression of neutrophil elastase in a mouse model of prostate cancer. J Immunol 2008; 180:6044-53; PMID:18424725

71. Gocheva V, Wang HW, Gadea BB, Show T, Hunter KE, Gaffney AL, et al. αT-β(+) induces carpomatopoietin pre-1 expression in tumour-associated macrophages to promote cancer growth and invasion. Gene Dev 2010; 24:241-55; PMID:20806976; http://dx.doi.org/10.1101/gad.184710
72. Gao Q, Qiu SJ, Fan J, Zhao J, Wang Y, Xue Y, et al. Interleukin-15 balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25:2056-63; PMID:17577016; http://dx.doi.org/10.1200/JCO.2006.09.4505.

73. Chen RJ, Zhao L, Shi HF, Ahmed TF, Feng XY, Zhang R. Functional regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection. Med Oncol 2011; PMID:21687826; http://dx.doi.org/10.1007/ s12032-011-0498-0.

74. Smolik H, Chilchova N, Tenza T, Wade J, Yamazaki A, Kitamura Y, et al. Interleukin-15+CD69+T cells ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immun Immunother 2010; 59:65-73; PMID:19908042; http://dx.doi.org/10.1007/s00262-009-0780-2.

75. Correale P, Rotundo MS, Del Vecchio MT, Remondo V,Ikeda H, Chikazawa N, Tasaka T, Wada J, Yamasaki S, et al. Pheno-type analysis of pro-tumor infiltrating lymphocytes reveals TH17 and Th1 targeting. Clin Cancer Res 2009; 15:3264-70; PMID:19391770; http://dx.doi.org/10.1158/1078-0432.CCR-08-1604.

76. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay NelH, et al. Prognostic value of tumor-infiltrating IL-17-producing cells in esophageal squamous cell carcinoma. Arch Oncol 2011; PMID:21245428; http://dx.doi.org/10.1097/CJA.0b013e3182f01046.

77. Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3-positive regulatory T cells is an independent predictor of improved clinical outcome in extranodal natural killer T-cell lymphoma. Haematologica 2008; 93:339-46; PMID:18018483; http://dx.doi.org/10.3324/haematol.11702.

78. De Meeus L, Beni M, Tanii E, Chovens D, Papa I, Rudele H, et al. Intratumoral helper type 2 cell infiltrates correlate with cancer-associated fibrosarcoma histotype driven lymphopoeitic production and reduced survival in pancreatic cancer. J Exp Med 2011; 208: 466-78; PMID:21393527; http://dx.doi.org/10.1084/jem.2010180176.

79. Hanai K, Braza PC, Maini CH, Li X, Thibon CJ, Dhalluin AM, et al. Phenotypic analysis of pro-tumor infiltrating lymphocytes reveals TH17 and Th1 targeting. Clin Cancer Res 2009; 15:3264-70; PMID:19391770; http://dx.doi.org/10.1158/1078-0432.CCR-08-1604.

80. Zhang JP, Tang X, Chao MS, Li L, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009; 51:88-96; PMID:19329213; http://dx.doi.org/10.1016/j.jhep.2009.02.049.

81. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Raspollini MR, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, and Th17) in human breast carcinomas. Blood 2009; 114:1481-9; PMID:19768064; http://dx.doi.org/10.1182/blood-2009-09-240249.

82. Li X, Pan K, Li XD, She KL, Zhao JJ, Wang W, et al. The accumulation and prognostic value of tumor infiltrating IL-17-producing cells in esophageal squamous cell carcinoma. PLoS One 2011; PMID:21245428; http://dx.doi.org/10.1371/journal.pone.0018219.

83. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610-8; PMID:21245428; http://dx.doi.org/10.1200/JCO.2010.30.5425.

84. Lv L, Pan K, Li XD, She KL, Zhao JJ, Wang W, et al. The accumulation and prognostic value of tumor infiltrating IL-17-producing cells in esophageal squamous cell carcinoma. PLoS One 2011; PMID:21245428; http://dx.doi.org/10.1371/journal.pone.0018219.

85. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Raspollini MR, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, and Th17) in human breast carcinomas. Blood 2009; 114:1481-9; PMID:19768064; http://dx.doi.org/10.1182/blood-2009-09-240249.

86. Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. In situ cytotoxic and memory T cells co-exist with regulatory T cells in breast cancer. J Exp Clin Cancer Res 2011; PMID:21678026; http://dx.doi.org/10.1007/s00088-011-1329-2.

87. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2011; 29:610-8; PMID:21245428; http://dx.doi.org/10.1200/JCO.2010.30.5425.

88. Cho Y, Miyamoto M, Kato K, Fukunaga A, Uehara T, Kennedy V, et al. CD8+ and CD4+ T cells co-exist with regulatory T cells in human tumor environments. Blood 2009; 114:1141-9; PMID:19641390; http://dx.doi.org/10.1182/blood-2008-10-198024.

89. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Bates GJ, Fox SB, et al. Tumoral neutrophils are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-5. Cancer Immunol Immunother 2011; 60:1419-30; PMID:21483813; http://dx.doi.org/10.1007/s00262-010-1108-0.

90. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009; 51:88-96; PMID:19329213; http://dx.doi.org/10.1016/j.jhep.2009.02.049.

91. Curiel TJ, Coukos G, Zou L, Shinu X, Cheng P, Metzner P, et al. Specific recruitment of regulatory T cells to cancer results from tumor intrinsic privilege and predicts improved survival. Nat Med 2004; 10:96-9; PMID:15323206; http://dx.doi.org/10.1093/annonc/mdh015.

92. Barra GF, Fox SB, Han C, Lask RD, Garcia JJ, Harim AA, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2011; 29:610-8; PMID:21245428; http://dx.doi.org/10.1200/JCO.2010.30.5425.

93. Gabdulai SF, Ansell NE, Stovall DD, Pandha HS, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, oesophageal and gastric cancer is an independent prognostic factor and is associated with significant elevation of the Th2 cytokine interleukin-5. Cancer Immunol Immunother 2011; 60:1419-30; PMID:21483813; http://dx.doi.org/10.1007/s00262-010-1108-0.

94. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Bates GJ, Fox SB, et al. Tumoral neutrophils are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-5. Cancer Immunol Immunother 2011; 60:1419-30; PMID:21483813; http://dx.doi.org/10.1007/s00262-010-1108-0.

95. Kryczek I, et al. The paradox of colorectal cancer. Cancer Immunol Immunother 2011; 60:1419-30; PMID:21483813; http://dx.doi.org/10.1007/s00262-010-1108-0.

96. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Bates GJ, Fox SB, et al. Tumoral neutrophils are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-5. Cancer Immunol Immunother 2011; 60:1419-30; PMID:21483813; http://dx.doi.org/10.1007/s00262-010-1108-0.